Kristen Osenga

Law Professor & Assoc. Dean @URLawSchool; mom & trail hiker/runner; loves strong patent rights, legal interpretation, and good red wine

[Kristen Osenga @ProfKOsenga]

Excellent new papers from @IPPolicyInst scholars about “patent thicket” and “evergreening” claims. The collection offers an important, evidence-based look at how post-approval innovation, patent timing, and generic competition actually work in practice. https://t.co/musdtgeeAP

[Kristen Osenga @ProfKOsenga]

@AccessibleMeds Products in all industries improve over time, and medicines are no different. Patents often protect different advances in formulation, manufacturing, delivery, and more. That's not a "patent thicket" -- it's continued innovation that improves treatments and benefits patients.

[Kristen Osenga @ProfKOsenga]

"Effective drug pricing policy should be based on empirical evidence — not unsupported patent narratives." Great new one-pager by @AdamMossoff on why strong patent rights are essential to research, investment, and innovation that improve and save lives: https://t.co/kwPIqBUj04

[Council for Innovation Promotion @Council4IP]

🎙️ Check out this episode of the IP Protection Matters podcast featuring insights from @ProfKOsenga, Associate Dean for Academic Affairs at the University of Richmond School of Law.

She discusses the link between IP and innovation, patent eligibility, so-called patent "evergreening," and more.

https://t.co/KA8GbrcFW0

[Kristen Osenga @ProfKOsenga]

Had a great conversation last week with @PatentGene at the @IPWatchdog Unleashed podcast. We talked about patents, IP policy, the dangers of mandatory "royalty-free" licensing -- and my career path! Listen here: https://t.co/5CTPYbv68m

[Kristen Osenga @ProfKOsenga]

@DeanBaker13 Patents exist for a limited period of time to encourage invention, investment, and risk-taking. Strong patent and IP protections are why technologies, medicines, and other innovations exist and improve over time. This "patent monopoly" narrative is wrong and misleading.

[Kristen Osenga @ProfKOsenga]

@RxPricing @IMAKglobal Post-approval R&D helps improve products over time. Patents often protect different types of advancements, like formulation, manufacturing, and delivery. That's not a patent thicket. It's how the system supports innovation and helps deliver better medicines for patients.

[Inventors Defense Alliance @DefendInventors]

Last week, IDA's Chief Policy Counselor, @ProfKOsenga, appeared on the @Clause8Podcast to discuss royalty-free tech standards, third-party litigation funding, and more. Check it out here: https://t.co/JdPkvdhZ3i

[Kristen Osenga @ProfKOsenga]

@Runaway_Rx Patents aren’t barriers -- they’re the foundation that makes new medicines possible. They provide a limited window to innovate, after which generics enter and scale access rapidly. That’s not a flaw in the system -- it’s exactly how it’s designed to work.

[Kristen Osenga @ProfKOsenga]

@GOPHELP The USPTO only grants patents for inventions that are novel and non-obvious. That’s true across all industries. Patents supporting post-approval R&D (new formulations, delivery methods, safer dosing, etc.) aren't trivial -- they reflect innovation patients rely on.

[Kristen Osenga @ProfKOsenga]

@emilysbremer Pro-tip...become an associate dean. All you'll have time to write are short papers. :)

[Kristen Osenga @ProfKOsenga]

"When the general public hears 'royalty-free,' the focus is on the word 'free.' But there's no such thing as a free lunch."

Great to speak to @mlexclusive about the threat that mandatory "royalty-free" licensing models pose to innovation. Read more here: https://t.co/2iwyvspf8V

[Inventors Defense Alliance @DefendInventors]

"Efficient infringement" works only when innovators lack the resources to fight back. It's why third-party litigation funding is so integral to leveling the playing field. Listen to @ProfKOsenga on @Clause8Podcast: https://t.co/JdPkvdhZ3i

[Kristen Osenga @ProfKOsenga]

@Runaway_Rx Patents don’t block access -- they enable innovation. Without them, many medicines wouldn’t exist. And once they expire, generics quickly take over. That’s not “gaming”-- that’s the model working as intended.

[Kristen Osenga @ProfKOsenga]

I enjoyed chatting with @EliMazour for @Clause8Podcast about the threats that mandatory "royalty-free" licensing models -- like those promoted by Big Tech's "Alliance for Open Media" -- pose to innovation in streaming technology. Listen here: https://t.co/g6cwZuhstl

[Kristen Osenga @ProfKOsenga]

@DrewForNevada gets it right: Big Tech is trying to suppress competition in streaming. Regulators must take note. Read his perspective here: https://t.co/bdkIkJPUjR

[MasonLEC @MasonLEC]

Thank you to @ProfKOsenga of @URLawSchool for joining @georgemasonlaw and @masonlec to present her #FormationStage paper to #ScaliaLaw students and faculty:

📑"Who's Suing Whom? Patent Litigant Characteristics & the Prevailing Patent Enforcement Narratives"

The #RibsteinWorkshop honors the legacy of academic pioneer Larry Ribstein and his commitment to #NewScholarship.

[Kristen Osenga @ProfKOsenga]

@RxPricing @Health_Affairs Post-approval R&D happens in every industry because products evolve over time. The patent system protects those improvements and encourages better outcomes for patients and consumers -- it doesn't create "patent thickets" that block competition.

[Kristen Osenga @ProfKOsenga]

@IMAKglobal Different patents often cover different scientific advances -- formulation, manufacturing, delivery, and more. This reflects the patent system functioning as intended by protecting continued innovation that makes medicines safer and more effective -- not blocking competition.

[Kristen Osenga @ProfKOsenga]

@realtahiramin @superwuster Saying that these patents “confer power” that others don't suggests they follow different rules. They don't. The same patent standards apply across industries. Post-approval R&D in every industry benefits consumers.